OOIR: Observatory of International Research

Papers

(The H4-Index of CTS-Clinical and Translational Science is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients	290
A systematic review of micro‐RNAs in aortic stenosis and cardiac fibrosis	130
Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan	96
How can real‐world evidence aid decision making during the life cycle of nonprescription medicines?	66
	62
Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies	62
Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors	57
Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial	51
New Insights Into Hepatic Impairment (HI) Trials	51
First, Do No Harm: Addressing AI's Challenges With Out‐of‐Distribution Data in Medicine	49
From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry	44
A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults	43
A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence	42
Effect of a Supratherapeutic Dose of Omaveloxolone on the Corrected QT Interval in Healthy Participants: A Randomized, Double‐Blind, Placebo‐ and Active‐Controlled, Three‐Way Crossover Stud	38
Modeling the Interplay Between Viral and Immune Dynamics in HIV: A Review and Mrgsolve Implementation and Exploration	37
Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome	36
Issue Information	34
Global Trends in the Value of Author Order Across Medical Publications: A Cross‐Sectional Bibliometric Study	34
National Prescribing Practices for Pediatric Dystonia Among Providers in the United States	33
CYP2D6 genotype and associated 5‐HT₃ receptor antagonist outcomes: A systematic review and meta‐analysis	32
AI In Action: Redefining Drug Discovery and Development	32
Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective	31
Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects	30
Pharmacometabolomics identifies candidate predictor metabolites of an L‐carnitine treatment mortality benefit in septic shock	28
Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males	28

Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies	28
Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia	26
Pharmacogenetic testing among patients with depression in a US managed care population	26